TITLE

Many FDA-approved drug trial results remain unpublished

AUTHOR(S)
Haigh, Christen
PUB. DATE
November 2008
SOURCE
Cardiology Today;Nov2008, Vol. 11 Issue 11, p43
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the supporting trials for U.S. Food and Drug Administration (FDA)-approved drugs, which are reported to remain unpublished five or more years after drug approval. Ida Sim of the University of California, San Francisco, cited that the results of trials supporting new drugs approved between 1998 and 2000 are not available in medical literature. It is also reported that there were 909 trials supporting 90 approved drugs in the FDA reviews.
ACCESSION #
35639371

 

Related Articles

  • IMPROVE MEDICAL DEVICES.  // Appliance Design;Mar2008, Vol. 56 Issue 3, p13 

    The article focuses on the claim by researchers from the University of California in San Francisco that the approval process for medical devices is not as rigorous as it is for pharmaceuticals. The researchers add that out of the thousands of medical devices submitted to the U.S. Food and Drug...

  • Publication is positively skewed. Bjorn, Genevive // Nature Medicine;Nov2008, Vol. 14 Issue 11, p1133 

    The article reports on the status of the publication of clinical trials for drugs submitted to the U.S. Food and Drug Administration (FDA) between 1998 and 2000. According to the author, positive results of clinical trials for drugs or devices have a higher chance of getting published in the...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;8/23/2008, Issue 560, p10 

    This section offers news briefs concerning medical care. Additional funding for the U.S. Food and Drug Administration (FDA) worth $275 million will be available in either March or April 2009. The Global Health Group at the University of California, San Francisco (UCSF) will receive a $3.5...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p37 

    The article offers news briefs relating to the ophthalmic business industry as of February 25, 2014. The European Medicines agency released marketing authorization for the preservative-free, single-dose formulation of Ganfort. Health Canada has approved the drug Jetrea for treating symptomatic...

  • Evidence shows certain drugs remain potent beyond expiration. WALKER, TRACEY // Managed Healthcare Executive;Nov2012, Vol. 22 Issue 11, p18 

    The article focuses on a study conducted by Lee Cantrell, professor at the University of California, San Francisco, and colleagues in which he analyzed 14 compounds which had expired 28 to 40 years earlier. It states that 12 compounds out of 14 compounds fulfill the requirements of the U.S. Food...

  • Nutrition 411. McVEIGH, GLORIA // Prevention;Jul2006, Vol. 58 Issue 7, p78 

    Presented here is a response to the question of why weight loss pills with ephedra, banned by the U.S. Food & Drug Administration (FDA), are still available for purchase. The author asserts that most are in violation of the ban, and the FDA continues to seize them. Cathy Dennehy, researcher at...

  • UCSF artificial kidney project tapped for accelerated FDA program.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that he U.S. Food and Drug Administration will be reviewing an implantable artificial kidney for dialysis patients which has been created by the University of California, San Francisco.

  • UCSF artificial kidney project tapped for accelerated FDA program.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article provides information on the University of California, San Francisco projects on creating implantable artificial kidney for dialysispatients selected as one of the first projects for more timely and collaborative review by the U.S. Food and Drug Administration.

  • CuraGen receives FDA approval for clinical trials.  // Fairfield County Business Journal;3/17/2003, Vol. 42 Issue 11, p17 

    Announces the U.S. Food and Drug Administration's approval of CuraGen Corp.'s investigational new drug application to initiate clinical trials for CG53135 for the treatment of oral mucositis. Results of preclinical studies of the protein.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics